inRegen’s technology has the potential to create new human tissues and kidneys (neo-tissues and neo-organs) by using the patient’s own (autologous) kidney cells. By contrast, organ transplantation from other donors (allogenic transplants) can be associated with organ rejection and failure. Further, the patient lives with the adverse effects of immunosuppression.
inRegen's patented technology uses multiple breakthroughs in tissue engineering and cell therapy products. While it has long been held that the body contains cells with regenerative power, inRegen's technology is able to identify these cells and harness them to create a specific neo-organ, with the potential to create a variety of neo-organs and tissues on a commercial scale.
inRegen’s kidney restoration process begins when a surgeon sends the patient’s biopsy to inRegen. inRegen is able to identify the patient’s own healthy progenitor cells, and formulate them into a personalized product that can be re-injected into the damaged kidney for repair and regeneration. When the physician injects the the Neo-Kidney Augment product into the patient’s diseased kidney, it is programmed to integrate into the damaged tissues and attract other healing cells, controlling inflammation, fibrosis and angiogenesis to form new functioning tissues and ultimately, a healthy kidney.
SAFETY & RESPONSIBILITY
Clinical Trials conducted to date
The Neo-Kidney Augment appears to be well tolerated in patients injected to date. There have been no identified adverse reactions shown to be related to the kidney augmenting product.